Deep dive into tesamorelin's FDA trial data, exactly how to interpret your IGF-1 results, what companion markers to track, and the protocols that actually move the needle based on your labs.
Tesamorelin is the only GH secretagogue with FDA approval and Phase 3 clinical trial data. It was approved in 2010 under the brand name Egrifta for HIV-associated lipodystrophy, a condition characterized by visceral fat accumulation driven by antiretroviral therapy.
That approval process generated the most rigorous clinical dataset of any peptide in common use today. The pivotal trials showed statistically significant reductions in visceral adipose tissue (VAT) of 15–18% over 26 weeks, improvements in IGF-1 levels averaging 60–80% from baseline, and improvements in lipid profiles — specifically triglycerides and non-HDL cholesterol.
Why this matters for longevity users: The FDA trial data gives tesamorelin something no research peptide has — a defined efficacy benchmark. You know what a clinical response looks like (60–80% IGF-1 increase at 26 weeks), which means you can assess whether YOUR protocol is working relative to what's been proven possible.
Tesamorelin works as a GHRH (growth hormone-releasing hormone) analog. It binds to GHRH receptors in the anterior pituitary and triggers GH secretion in a pulsatile pattern that closely mimics the body's natural rhythm. This is mechanistically distinct from GH itself (which provides a constant supraphysiologic level) and from GHRPs like ipamorelin (which work through the ghrelin receptor). The pulsatile pattern matters — it's what preserves the GH feedback loop and prevents the desensitization seen with continuous GH administration.
IGF-1 (Insulin-like Growth Factor 1) is produced primarily by the liver in response to GH signaling. It is the main downstream effector of GH — most of what we attribute to "growth hormone" is actually IGF-1 doing the work at the tissue level.
Reference ranges versus optimal ranges are not the same thing. Standard lab reference ranges are built from population averages, which include sedentary, unhealthy individuals. They are not optimal targets for longevity-focused users.
Age-stratified optimal ranges (not just reference ranges):
These are ranges associated with longevity-positive outcomes in prospective studies. The goal is not maximum IGF-1 — there is a U-shaped curve. Very high IGF-1 (>400 ng/mL chronically) is associated with increased cancer risk in epidemiological data. The goal is the upper third of age-appropriate optimal range.
The companion marker you must track: IGFBP-3 (IGF-1 Binding Protein 3). IGF-1 circulates bound to binding proteins — IGFBP-3 carries approximately 80% of all IGF-1 in the blood. Free IGF-1 is the biologically active fraction. Without knowing IGFBP-3, your IGF-1 number has limited interpretive value. Low IGFBP-3 with high total IGF-1 may mean more free (potentially supraphysiologic) IGF-1. Request both on your panel.
Standard dosing from the FDA trials: 2 mg subcutaneous injection daily. Many longevity-focused users run 1 mg daily (half the clinical dose) with meaningful IGF-1 response and fewer side effects, particularly water retention.
Injection timing: Bedtime, fasted 2–3 hours prior. This is not arbitrary. GH is naturally secreted in its largest pulse approximately 60–90 minutes after sleep onset. Tesamorelin at bedtime augments this natural pulse rather than creating an isolated spike at a random time of day. The fasting requirement exists because insulin — elevated after meals — suppresses GH release. You are competing with your own insulin if you inject after eating.
Days on/days off: The clinical trials used daily administration. However, pituitary downregulation (tachyphylaxis) is a known risk with continuous GHRH stimulation. Many experienced users and prescribers use a 5-on-2-off schedule (weekdays on, weekends off) to maintain receptor sensitivity. IGF-1 has a half-life of 12–15 hours, so two days off does not meaningfully drop your levels but may preserve long-term responsiveness.
Cycle length: 6–12 months is common, with lab monitoring at 6–8 weeks and at cycle end. The FDA trials ran 26 weeks. Many users continue indefinitely with quarterly lab monitoring given tesamorelin's established safety profile at clinical doses.
For shift workers: The fasting and timing requirements are relative to YOUR sleep, not clock time. If your bedtime is 8 AM, inject at 8 AM fasted. Circadian disruption does blunt GH response — research consistently shows shift workers have lower GH pulsatility — but tesamorelin still works. Expect your IGF-1 response to be 10–20% lower than published averages if you work nights. Mitigating factors: melatonin (0.5 mg 30 min before sleep), sleep environment optimization, and magnesium glycinate for sleep quality.
Incorrect IGF-1 testing is one of the most common sources of confusing or misleading results. These variables significantly affect your number:
Draw timing: Morning draw (7–10 AM) is standard. IGF-1 has diurnal variation — it is highest in the early morning and lower in the afternoon and evening. Drawing at 3 PM on one test and 8 AM on the next will make your results look like they changed when they may not have.
Time since last injection: Draw 12–16 hours after your last tesamorelin injection. This represents the nadir (lowest point) of your IGF-1 response, which is the most reproducible and interpretable baseline. If you draw 2 hours post-injection, you'll capture an acute spike that doesn't reflect your actual sustained level.
Fasting vs fed state: IGF-1 is not directly affected by acute food intake the way insulin or glucose are, but protein intake influences IGF-1 over days to weeks. Acutely, you don't need to fast for an IGF-1 draw — but keep your diet consistent between tests.
Sleep quality: Poor sleep (less than 6 hours, or fragmented sleep) the night before your draw can suppress IGF-1 by 15–25%. If you slept terribly, wait for a better night before drawing labs. This is particularly relevant for shift workers who should draw after their best sleep block.
Exercise: Intense exercise in the 24 hours before an IGF-1 draw acutely elevates levels. For consistency, avoid intense training the day before your draw.
Running tesamorelin without monitoring these markers is flying blind:
Fasting glucose and HbA1c: GH causes physiological insulin resistance. This is a known mechanism — GH shifts substrate utilization toward fat burning and away from glucose, which secondarily raises blood glucose. At clinical doses of tesamorelin, fasting glucose may rise 3–7 mg/dL. This is generally benign in metabolically healthy individuals. However, if your baseline fasting glucose is already 95–99 (impaired fasting), tesamorelin could push you into the 100+ range. Check glucose and HbA1c at baseline and 8 weeks.
Fasting insulin: More sensitive than glucose for early insulin resistance. If fasting insulin rises above 10 uIU/mL during a tesamorelin cycle, consider dose reduction, adding berberine 500 mg twice daily, or incorporating zone 2 cardio to improve insulin sensitivity.
IGF-1 and IGFBP-3: As discussed — both, not just IGF-1 alone.
Thyroid panel (TSH, free T4, free T3): GH secretagogues can unmask subclinical hypothyroidism by increasing conversion demands. If you feel fatigued despite rising IGF-1, check thyroid. TSH rising above 2.5 warrants free hormone testing.
Echocardiogram or cardiac markers (for long-term users): Supraphysiologic GH levels cause cardiomegaly over time. At therapeutic tesamorelin doses this is not established as a risk, but long-term users (1+ year) monitoring their protocol comprehensively should consider baseline echo if they have other cardiovascular risk factors.
Tesamorelin acts on GHRH receptors (stimulating GH release). Ipamorelin acts on ghrelin receptors (also stimulating GH release, through an independent pathway). They are mechanistically complementary — they hit different buttons to produce the same output.
The combination produces a GH pulse that is larger than either compound alone, because both pathways are simultaneously activated. Research on GHRH + GHRP combinations consistently shows synergistic (not merely additive) GH release.
Protocol for the combination:
The bedtime stack is the most common approach — both compounds augment the natural sleep GH pulse simultaneously. Some users split them: tesamorelin at bedtime, ipamorelin in the morning or pre-workout, to create a second GH pulse during the day.
Expected IGF-1 response with the combination: 80–120% above baseline at 8–12 weeks for well-responding individuals. Users in the lower range of the clinical trial response (40–60% increase) often see a significant jump when ipamorelin is added.
Enter your blood work in MyProtocolStack and let StackAI generate personalized insights — hormone patterns, cardiovascular risk, nutrient gaps, and protocol recommendations based on your actual numbers.
Start Free — No Credit Card →